Population pharmacoepigenomics

Handbook of Epigenetics

Volumn , Issue , 2011, Pages 511-517

  Peedicayil, Jacob ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882916406     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375709-8.00031-9     Document Type: Chapter

References (62)

1. Peedicayil J Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics 2008, 9:1785-1786.
2. Szyf M Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics 2004, 2:357-377.
3. Allis CD, Jenuwein T, Reinberg D Overview and concepts. Epigenetics 2007, 23-61. Cold Spring Harbor Laboratory Press, New York. C.D. Allis, T. Jenuwein, D. Reinberg (Eds.).
4. Egger G, Liang G, Aparicio A, Jones PA Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
5. Peedicayil J Epigenetic therapy-a new development in pharmacology. Indian J Med Res 2006, 123:17-24.
6. Yoo CB, Jones PA Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37-50.
7. Mai A, Altucci L Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009, 41:199-213.
8. Richards EJ Population epigenetics. Curr Opin Genet Dev 2008, 18:221-226.
9. Brena RM, Huang TH-M, Plass C Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med 2006, 84:365-377.
10. Mulero-Navarro S, Esteller M Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008, 68:1-11.
11. Laird PW The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253-266.
12. Paluszczak J, Baer-Dubowska W Epigenetic diagnostics of cancer-the application of DNA methylation markers. J Appl Genet 2006, 47:365-375.
13. Toyota M, Suzuki H, Yamashita T, Hirata K, Imai K, Tokino T, et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci 2009, 100:787-991.
14. McCabe MT, Brandes JC, Vertino PM Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009, 15:3927-3937.
15. Kuzawa CW, Sweet E Epigenetics and the embodiment of race: developmental origins of US racial disparities in cardiovascular health. Am J Hum Biol 2009, 21:2-15.
16. Woodson K, Hayes R, WideroffL, Villaruz L, Tangrea J Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US blacks and whites. Prostate 2003, 55:199-205.
17. Piyathilake CJ, Henao O, Frost AR, Macaluso M, Bell WC, Johanning GL, et al. Race- and age-dependent alterations in global methylation of DNA in squamous cell carcinoma of the lung (United States). Cancer Causes Control 2003, 14:37-42.
18. Fukuzawa R, Breslow NE, Morison IM, Dwyer P, Kusafuka T, Kobayashi Y, et al. Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 2004, 363:446-451.
19. Dumitrescu RG, Marian C, Krishnan SS, Spear SL, Kallakury BV, Perry DJ, et al. Familial and racial determinants of tumor suppressor genes promoter hypermethylation in breast tissues from healthy women. J Cell Mol Med 2010, (in press).
20. Boardman LA, Lanier AP, French AJ, Schowalter KV, Burgart LJ, Koller KR, et al. Frequency of defective DNA mismatch repair in colorectal cancer among the Alaska native people. Cancer Epidemiol Biomarkers Prev 2007, 16:2344-2350.
21. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
22. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
23. Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 2007, 46:336-347.
24. Peedicayil J Epigenetic biomarkers in psychiatric disorders. Br J Pharmacol 2008, 155:795-796.
25. Campión J, Milagro FI, Martinez JA Individuality and epigenetics in obesity. Obesity Rev 2009, 10:383-392.
26. Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, et al. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease?. J Intern Med 2007, 261:488-499.
27. Bradbury J Human epigenome project-up and running. Plos Biol 2003, 1:316-319.
28. American Association for Cancer Research Human Epigenome Task Force; European Union, Network of Excellence, Scientific Advisory Board Moving AHEAD with an international human epigenome project. Nature 2008, 454:711-715.
29. Gottesman MM Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
30. Perez-Plasencia C, Duenas-Gonzalez A Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?. Mol Cancer 2006, 5:27.
31. Humeniuk R, Mishra PJ, Bertino JR, Banerjee D Molecular targets for epigenetic therapy of cancer. Curr Pharm Biotechnol 2009, 10:161-165.
32. Sausville EA, Longo DL, et al. Principles of cancer treatment. Harrison's principles of internal medicine 2008, Vol I:514-533. McGraw Hill, New York.
33. Brown R, Glasspool R Epigenetic modulation of resistance to chemotherapy?. Ann Oncol 2007, 18:1429-1430.
34. Epstein RJ, Leung TW Reversing hepatocellular carcinoma progression by using networked biological therapies. Clin Cancer Res 2007, 13:11-17.
35. Plimack ER, Stewart DJ, Issa J-PJ Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol 2007, 25:4519-4521.
36. Bots M, Johnstone RW Rational combinations using HDAC inhibitors. Clin Cancer Res 2009, 15:3970-3977.
37. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1gene promoter. Cancer Res 2000, 60:6039-6044.
38. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 2005, 4:1505-1514.
39. Suzuki M, Shinohara F, Nishimura K, Echigo S, Rikiishi H Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int J Oncol 2007, 31:1449-1456.
40. El-Khoury V, Breuzard G, Fourré N, Dufer J The histone deactylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br J Cancer 2007, 97:562-573.
41. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocyte leukaemia cells. Br J Haematol 2009, 144:41-52.
42. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15:2818-2828.
43. Cobiac L Epigenomics and nutrition. Forum Nutr 2007, 60:31-41.
44. Waterland RA, Jirtle RL Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 2004, 20:63-68.
45. Mathers JC Epigenomics: a basis for understanding individual differences?. Proc Nutr Soc 2008, 67:390-394.
46. Kaushansky K, Kipps TJ Hematopoietic agents: Growth factors, minerals, and vitamins. The pharmacological basis of therapeutics 2006, 1433-1465. McGraw-Hill, New York. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
47. McMillen IC, Robinson JS Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev 2005, 85:571-633.
48. Waterland RA, Michels KB Epigenetic epidemiology of the developmental origins hypothesis. Annu Rev Nutr 2007, 27:363-388.
49. Stover PJ, Garza C Nutrition and developmental biology-implications for public health. Nutr Rev 2006, 64:S60-S71.
50. Morgan HD, Sutherland HG, Martin DI, Whitelaw E Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 1999, 23:314-318.
51. WolffGL, Kodell RL, Moore SR, Cooney CA Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. Faseb J 1998, 12:949-957.
52. Waterland RA, Jirtle RL Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003, 23:5293-5300.
53. Jirtle RL, Skinner MK Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007, 8:253-262.
54. Sinclair KD, Allegrucci C, Singh R, Gardner DS, Sebastian S, Bispham J, et al. DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci USA 2007, 104:19351-19356.
55. Burdge GC, Lillycrop KA, Jackson AA Nutrition in early life, and risk of cancer and metabolic disease: alternative endings in an epigenetic tale?. Br J Nutr 2009, 101:619-630.
56. Zeisel SH Epigenetic mechanisms for nutrition determinants of later health outcomes. Am J Clin Nutr 2009, 89:1488S-1493S.
57. Junien C, Nathanielsz P Report on the IASO Stock Conference 2006: early and lifelong environmental epigenomic programming of metabolic syndrome, obesity and type II diabetes. Obes Rev 2007, 8:487-502.
58. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci USA 2008, 105:17046-17049.
59. Fraga MF, Esteller M Epigenetics and aging: the targets and the marks. Trends Genet 2007, 23:413-418.
60. Calvanese V, Lara E, Kahn A, Fraga MF the role of epigenetics in aging and age-related diseases. Ageing Res Rev 2009, 8:268-276.
61. Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004, 4:65.
62. Wang A-G, Fang W, Han Y-H, Cho S-M, Choi JY, Lee KH, et al. Expression of the RERG gene is gender-dependent in hepatocellular carcinoma and regulated by histone deacetyltransferases. J Korean Med Sci 2006, 21:891-896.